# US 2020/0347036 A1 · Solid forms of an hiv protease inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347036 A1
- Document ID: US20200347036A1
- Status: Published application
- Kind: A1
- Application number: 16/849,201
- Filed: 2020-04-15
- Published: 2020-11-05
- Earliest claimed: 2019-04-17
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Bing Shi
- Web page: https://patentgrep.com/patent/US20200347036A1

## CPC

- A61P 31/18: for HIV
- C07D 403/14: containing three or more hetero rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to pharmaceutically acceptable salts and crystalline forms thereof, of a compound which is (S)-2-(4-chloro-3-(1-(difluoromethyl)-1H-1,2,4-triazol-5-yl)phenyl)-2-((R)-4-(4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)phenyl)-2-imino-5-oxo-4-(3,3,3-trifluoro-2,2-dimethylpropyl)imidazolidin-1-yl)ethyl (1- (difluoromethyl)cyclopropyl)carbamate, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

## Claims

### Claim 1

A crystalline form of (S)-2-(4-chloro-3-(1-(difluoromethyl)-1H-1,2,4-triazol-5-yl)phenyl)-2-((R)-4-(4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)phenyl)-2-imino-5-oxo-4-(3,3,3-trifluoro-2,2-dimethylpropyl)imidazolidin-1-yl)ethyl (1-(difluoromethyl)cyclopropyl)carbamate hydrochloride salt, which is selected from crystalline Form I, crystalline Form II, and crystalline Form III.

### Claim at position 2

-3. (canceled)

### Claim 4 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form I is characterized by an XRPD pattern comprising three peaks, in terms of 2-theta±0.2°, selected from 6.2°, 10.4°, 12.6°, 13.7°, 16.3°, 17.8°, 21.7°, 22.2°, and 26.8°.

### Claim at position 4

-11. (canceled)

### Claim 12 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form I is characterized by an XRPD pattern substantially as shown in FIG. 3.

### Claim 13 (depends on 1)

The crystalline form claim 1, wherein the crystalline Form I is characterized by a DSC thermogram having a melting onset of about 140° C.

### Claim 14 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form I is characterized by a DSC thermogram substantially as shown in FIG. 5.

### Claim 15 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form II is characterized by an XRPD pattern comprising three peaks, in terms of 2-theta±0.2°, selected from 6.5°, 7.2°, 8.5°, 11.3°, 13.4°, 14.3°, 15.7°, 17.0°, and 17.7°.

### Claim at position 9

-22. (canceled)

### Claim 23 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form II is characterized by an XRPD pattern substantially as shown in FIG. 8.

### Claim 24 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form II is characterized by a DSC thermogram having a melting onset of about 141° C.

### Claim 25 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form II is characterized by a DSC thermogram substantially as shown in FIG. 10.

### Claim 26 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form III is characterized by an XRPD pattern comprising three peaks, in terms of 2-theta±0.2°, selected from 6.3°, 6.6°, 10.9°, 13.7°, 15.3°, 17.3°, 18.5°, 20.0°, and 25.1°.

### Claim at position 14

-34. (canceled)

### Claim 35 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form III is characterized by an XRPD pattern substantially as shown in FIG. 14.

### Claim 36 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form III is characterized by a DSC thermogram having a melting onset of about 145° C.

### Claim 37 (depends on 1)

The crystalline form of claim 1, wherein the crystalline Form III is characterized by a DSC thermogram substantially as shown in FIG. 16.

### Claim 38

A crystalline form of (S)-2-(4-chloro-3-(1-(difluoromethyl)-1H-1,2,4-triazol-5-yl)phenyl)-2-((R)-4-(4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)phenyl)-2-imino-5-oxo-4-(3 ,3 ,3-trifluoro-2,2-dimethylpropyl)imidazolidin-1-yl)ethyl (1-(difluoromethyl)cyclopropyl)carbamate phosphate salt, which is crystalline Form I.

### Claim at position 19

-40. (canceled)

### Claim 41 (depends on 38)

The crystalline form of claim 38, wherein the crystalline Form I is characterized by an XRPD pattern comprising three peaks, in terms of 2-theta±0.2°, selected from 6.8°, 11.8°, 12.2°, 13.4°, 16.1°, 17.9°, 21.2°, 22.0°, and 25.3°.

### Claim at position 21

-48. (canceled)

### Claim 49 (depends on 38)

The crystalline form of claim 38, wherein the crystalline Form I is characterized by an XRPD pattern substantially as shown in FIG. 20.

### Claim 50 (depends on 38)

The crystalline form of claim 38, wherein the crystalline Form I is characterized by a DSC thermogram having a melting onset of about 137° C.

### Claim 51 (depends on 38)

The crystalline form of claim 38, wherein the crystalline Form I is characterized by a DSC thermogram substantially as shown in FIG. 22.

### Claim 52

A crystalline form of (S)-2-(4-chloro-3-(1-(difluoromethyl)-1H-1,2,4-triazol-5-yl)phenyl)-2-((R)-4-(4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)phenyl)-2-imino-5-oxo-4-(3,3,3-trifluoro-2,2-dimethylpropyl)imidazolidin-1-yl)ethyl (1-(difluoromethyl)cyclopropyl)carbamate maleate salt, which is crystalline Form I.

### Claim at position 26

-54. (canceled)

### Claim 55 (depends on 52)

The crystalline form of claim 52, wherein the crystalline Form I is characterized by an XRPD pattern comprising three peaks, in terms of 2-theta±0.2°, selected from 6.0°, 13.3°, 14.4°, 17.2°, 18.2°, 19.2°, 19.6°, 24.6°, and 26.5°.

### Claim at position 28

-62. (canceled)

### Claim 63 (depends on 52)

The crystalline form of claim 52, wherein the crystalline Form I is characterized by an XRPD pattern pattern substantially as shown in FIG. 24.

### Claim 64 (depends on 52)

The crystalline form of claim 52, wherein the crystalline Form I is characterized by a DSC thermogram having a melting onset of about 209° C.

### Claim 65 (depends on 52)

The crystalline form of claim 52, wherein the crystalline Form I is characterized by a DSC thermogram substantially as shown in FIG. 27.

### Claim 66

A crystalline form of (S)-2-(4-chloro-3-(1-(difluoromethyl)-1H-1,2,4-triazol-5-yl)phenyl)-2-((R)-4-(4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)phenyl)-2-imino-5-oxo-4-(3 ,3 ,3-trifluoro-2,2-dimethylpropyl)imidazolidin-1-yl)ethyl (1-(difluoromethyl)cyclopropyl)carbamate succinate salt, which is crystalline Form I.

### Claim at position 33

-68. (canceled)

### Claim 69 (depends on 66)

The crystalline form of claim 66, wherein the crystalline Form I is characterized by an XRPD pattern comprising three peaks, in terms of 2-theta±0.2°, selected from 6.0°, 13.3°, 14.3°, 17.1°, 18.3°, 19.2°, 19.6°, 24.6°, and 26.4°.

### Claim at position 35

-76. (canceled)

### Claim 77 (depends on 66)

The crystalline form of claim 66, wherein the crystalline Form I is characterized by an XRPD pattern substantially as shown in FIG. 29.

### Claim 78 (depends on 66)

The crystalline form of claim 66, wherein the crystalline Form I is characterized by a DSC thermogram having a melting onset of about 154° C.

### Claim 79 (depends on 66)

The crystalline form of claim 66, wherein the crystalline Form I is characterized by a DSC thermogram substantially as shown in FIG. 32.

### Claim 80

A crystalline form of (S)-2-(4-chloro-3-(1-(difluoromethyl)-1H-1,2,4-triazol-5-yl)phenyl)-2-((R)-4-(4-(2-cyclopropyl-2H-1,2,3-triazol-4-yl)phenyl)-2-imino-5-oxo-4-(3,3,3-trifluoro-2,2-dimethylpropyl)imidazolidin-1-yl)ethyl (1-(difluoromethyl)cyclopropyl)carbamate hemisuccinate salt, which is crystalline Form I.

### Claim at position 40

-82. (canceled)

### Claim 83 (depends on 80)

The crystalline form of claim 80, wherein the crystalline Form I is characterized by an XRPD pattern comprising three peaks, in terms of 2-theta±0.2°, selected from 6.5°, 8.7°, 15.1°, 17.4°, 17.9°, 18.5°, 19.1°, 19.8°, and 21.1°.

### Claim at position 42

-90. (canceled)

### Claim 91 (depends on 80)

The crystalline form of claim 80, wherein the crystalline Form I is characterized by an XRPD pattern substantially as shown in FIG. 34.

### Claim 92 (depends on 1)

A pharmaceutical composition comprising the crystalline form of claim 1, and at least one pharmaceutically acceptable excipient.

### Claim 93 (depends on 1)

A method of treating or preventing a human immunodeficiency virus (HIV) infection comprising administering a therapeutically effective amount of the crystalline form of claim 1 to a subject in need thereof.

### Claim 94 (depends on 93)

The method of claim 93, wherein the method comprises administering the crystalline form in combination with one, two, three, or four additional therapeutic agents.

### Claim 95 (depends on 94)

The method of claim 94, wherein the additional therapeutic agents are selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors, cell therapies, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, CD4 modulators, CD4 antagonists, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, CCR5 chemokine antagonists, CCR5 gene modulators, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, hyaluronidase inhibitors, Nef antagonists, Nef inhibitors, Protease-activated receptor-1 antagonists, TNF alpha ligand inhibitors, PDE4 inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, long acting HIV regimens, contraceptives, or any combinations thereof.

### Claim 96 (depends on 94)

The method of claim 94, wherein the additional therapeutic agents are selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, or any combinations thereof.

### Claim 97 (depends on 94)

The method of claim 94, wherein the additional therapeutic agents are selected from the group consisting of 4′-ethynyl-2-fluoro-2′-deoxyadenosine, bictegravir or a pharmaceutically acceptable salt thereof, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate.

### Claim 98 (depends on 94)

The method of claim 94, wherein the additional therapeutic agents are selected from the group consisting of 4′-ethynyl-2-fluoro-2′-deoxyadenosine, bictegravir or a pharmaceutically acceptable salt thereof, tenofovir alafenamide, tenofovir alafenamide fumarate and tenofovir alafenamide hemifumarate.

### Claim at position 51

-112. (canceled)
